4 active not recruiting, 3 completed, 2 recruiting, 1 enrolling by invitation. 7 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 3, Recruiting 2, Completed 1, Enrolling by invitation 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow XEN1101: new trials by email Literature Review of XEN1101 trials Research Report on XEN1101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) Azetukalner, Placebo - Bipolar Disorder, Bipolar Depression | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 400 | 2025-08-08 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2025-07-08 | 2026-10-15 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2024-12-20 | 2026-10-13 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) XEN1101, Placebo - Focal Onset Seizures | Phase 3 | Recruiting | Xenon Pharmaceuticals Inc. | 360 | 2023-05-09 | 2026-10-08 |
| An Open-label Study of XEN1101 in Epilepsy XEN1101 - Focal Epilepsy, Tonic-Clonic Seizures | Phase 3 | Enrolling by invitation | Xenon Pharmaceuticals Inc. | 880 | 2023-04-25 | 2026-10-08 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures XEN1101, Placebo - Primary Generalized Tonic-Clonic Seizures | Phase 3 | Recruiting | Xenon Pharmaceuticals Inc. | 160 | 2023-02-14 | 2026-10-08 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures XEN1101, Placebo - Focal Onset Seizures | Phase 3 | Completed | Xenon Pharmaceuticals Inc. | 380 | 2022-11-18 | 2026-05-14 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder XEN1101 10 mg, XEN1101 20 mg, Placebo - Major Depressive Disorder | Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 168 | 2022-05-19 | 2026-09-21 |
| XEN1101 for Major Depressive Disorder XEN1101, Placebo - Major Depressive Disorder | Phase 2 | Completed | James Murrough | 44 | 2021-10-19 | 2025-04-02 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy XEN1101 - Focal Epilepsy | Phase 2 | Active not recruiting | Xenon Pharmaceuticals Inc. | 325 | 2019-01-30 | 2024-09-24 |
Epilepsy (5) · Depression (4) · Depressive Disorder, Major (4) · Seizures (3) · Epilepsies, Partial (2) · Anhedonia (1) · Bipolar Disorder (1)
Xenon Pharmaceuticals Inc. (9) · James Murrough (1)
United States (10) · Germany (7) · Spain (7) · Bulgaria (5) · Italy (5) · Poland (5) · Argentina (4) · Australia (4) · Canada (4) · Chile (4) · Czechia (4) · Mexico (4) · Portugal (4) · United Kingdom (4) · Austria (3)
PMID 37812429, PMID 40423966, PMID 41001561
2018 (1), R33MH111932 (1)